| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 9G1A824CC2 |
Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Schizophrenia | Phase 1 | ClinicalTrials |
| Schizophrenia | Phase 1 | ClinicalTrials |
| Deafness; Hearing Loss; Hearing Loss, Sensorineural | Phase 1 | ClinicalTrials |
| Schizophrenia | Phase 1 | ClinicalTrials |
| Cognitive Dysfunction; Schizophrenia | Phase 2 | ClinicalTrials |
| Schizophrenia | Phase 1 | ClinicalTrials |
| Cognitive Dysfunction; Schizophrenia | Phase 1 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1258963-59-5 |
| ChEMBL | CHEMBL3707379 |
| FDA SRS | 9G1A824CC2 |
| PubChem | 49853967 |
CONTENTS